Prof Sacks, USA reviews the available data about various PPAR alpha gamma dual agonists (Saroglitazar, Aleglitazar, Muraglitazar and Tesaglitazar). He highlights the limitations on these therapies, such as increase in cardiovascular events or renal problems.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In